Logo

Neurimmune Expands its Collaboration with Ono to Develop Monoclonal Antibody Therapies for the Treatment of Neurodegenerative Diseases

Share this

Neurimmune Expands its Collaboration with Ono to Develop Monoclonal Antibody Therapies for the Treatment of Neurodegenerative Diseases

Shots:

  • Neurimmune to receive an up front, research fees & is eligible to receive milestones on the research and development progress along with royalties on product sales. Additionally, both companies focus to generate and validate human-derived mAb against Ono’s newly selected drug targets by using Neurimmune’s reverse translational medicine (RTM) technology platform
  • Ono will obtain exclusive rights for the development and commercialization globally of antibody products that emerge from the collaboration
  • In Nov 2017, Ono entered into a collaboration with Neurimmune to identify and develop human Abs using the RTM technology platform

Ref: Neurimmune | Image: PR Newswire

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions